105 related articles for article (PubMed ID: 23686116)
1. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Clavio M; Cruciani F; Minetto P; Guolo F; Ballerini F; Marani C; De Astis E; Aquino S; Bergamaschi M; Mitscheunig L; Grasso R; Colombo N; Ghiggi C; Lovera D; Pastori G; Avenoso D; Miglino M; Gobbi M
Ann Hematol; 2013 Oct; 92(10):1309-18. PubMed ID: 23686116
[TBL] [Abstract][Full Text] [Related]
2. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients.
Clavio M; Vignolo L; Albarello A; Varaldo R; Pierri I; Catania G; Balocco M; Michelis G; Miglino M; Manna A; Balleari E; Carella AM; Sessarego M; Van Lint MT; Bacigalupo A; Gobbi M
Br J Haematol; 2007 Jul; 138(2):186-95. PubMed ID: 17593025
[TBL] [Abstract][Full Text] [Related]
3. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
4. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
[TBL] [Abstract][Full Text] [Related]
5. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
[TBL] [Abstract][Full Text] [Related]
6. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.
Russo D; Malagola M; de Vivo A; Fiacchini M; Martinelli G; Piccaluga PP; Damiani D; Candoni A; Michielutti A; Castelli M; Testoni N; Ottaviani E; Rondoni M; Pricolo G; Mazza P; Zuffa E; Zaccaria A; Raspadori D; Bocchia M; Lauria F; Bonini A; Avanzini P; Gugliotta L; Visani G; Fanin R; Baccarani M
Br J Haematol; 2005 Oct; 131(2):172-9. PubMed ID: 16197446
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
[No Abstract] [Full Text] [Related]
8. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
Iacobucci I; Lonetti A; Candoni A; Sazzini M; Papayannidis C; Formica S; Ottaviani E; Ferrari A; Michelutti A; Simeone E; Astolfi A; Abbenante MC; Parisi S; Cattina F; Malagola M; Russo D; Damiani D; Gherlinzoni F; Gottardi M; Baccarani M; Fanin R; Martinelli G
Pharmacogenomics J; 2013 Aug; 13(4):335-41. PubMed ID: 22584460
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.
Kim I; Koh Y; Yoon SS; Park S; Kim BK; Kim DY; Lee JH; Lee KH; Cheong JW; Lee HK; Kim SH; Kim H; Joo YD; Lee SM; Won JH; Park SK; Hong DS; Kim SH; Sohn SK; Kim CS; Park E; Kim MK; Park MR; Lee JH; Min YH;
Am J Hematol; 2013 Jan; 88(1):10-5. PubMed ID: 23077109
[TBL] [Abstract][Full Text] [Related]
10. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
Martin MG; Augustin KM; Uy GL; Welch JS; Hladnik L; Goyal S; Tiwari D; Monahan RS; Reichley RM; Cashen AF; Stockerl-Goldstein K; Westervelt P; Abboud CN; Dipersio JF; Vij R
Am J Hematol; 2009 Nov; 84(11):733-7. PubMed ID: 19806665
[TBL] [Abstract][Full Text] [Related]
11. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With
Russell NH; Wilhelm-Benartzi C; Othman J; Dillon R; Knapper S; Batten LM; Canham J; Hinson EL; Betteridge S; Overgaard UM; Gilkes A; Potter N; Mehta P; Kottaridis P; Cavenagh J; Hemmaway C; Arnold C; Freeman SD; Dennis M;
J Clin Oncol; 2024 Apr; 42(10):1158-1168. PubMed ID: 38215358
[TBL] [Abstract][Full Text] [Related]
13. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients.
Borthakur G; Ravandi F; Patel K; Wang X; Kadia T; DiNardo C; Garcia-Manero G; Pemmaraju N; Jabbour EJ; Takahashi K; Ohanian M; Daver N; Alvarado Y; Brandt M; Pierce S; Kantarjian H
Am J Hematol; 2022 Nov; 97(11):1427-1434. PubMed ID: 36053747
[TBL] [Abstract][Full Text] [Related]
15. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
[TBL] [Abstract][Full Text] [Related]
16. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
17. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Tsimberidou A; Estey E; Cortes J; Thomas D; Faderl S; Verstovsek S; Garcia-Manero G; Keating M; Albitar M; O'Brien S; Kantarjian H; Giles F
Cancer; 2003 Mar; 97(6):1481-7. PubMed ID: 12627513
[TBL] [Abstract][Full Text] [Related]
18. Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
Pilorge S; Rigaudeau S; Rabian F; Sarkozy C; Taksin AL; Farhat H; Merabet F; Ghez S; Raggueneau V; Terré C; Garcia I; Renneville A; Preudhomme C; Castaigne S; Rousselot P
Am J Hematol; 2014 Apr; 89(4):399-403. PubMed ID: 24375467
[TBL] [Abstract][Full Text] [Related]
19. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
